SCHEMBL31662281

SCHEMBL31662281

COCOc1cc(-c2nc(OC(C)C)c3c(NCCCNC(=O)OC(C)(C)C)nc([S+](C)[O-])nc3c2F)c2c(C#C[Si](C(C)C)(C(C)C)C(C)C)c(F)ccc2c1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.33
STK17B O94768 1/20 0.31
STK17A Q9UEE5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662358 0.91 BRD4 (0.34) BRD4STK17BSTK17A
SCHEMBL31662177 0.83
SCHEMBL31662139 0.81
SCHEMBL31662263 0.78
SCHEMBL31048952 0.77 JAK2 (0.32)
SCHEMBL31662309 0.75
SCHEMBL31662364 0.75
SCHEMBL31235157 0.74
SCHEMBL31662034 0.73
SCHEMBL30850145 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed